Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032929 · ClinicalTrials.gov registry record · Phase 3
Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1
A Phase 3 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 3
- Development phase
- 269
- Enrollment target
NCT00032929 is a Phase 3 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 269 participants.
The verdict
NCT00032929, a Phase 3 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 269 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.
Interventions
- DRUG Selegiline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2001-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032929
The ClinicalTrials.gov registry entry for NCT00032929 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selegiline is the first listed.
NCT00032929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00032929 about?
NCT00032929 is a clinical study titled "Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1". The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.
What is the current status of trial NCT00032929?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2001-03.
What interventions are being tested in trial NCT00032929?
The interventions under investigation include: Selegiline (DRUG).
Who is sponsoring clinical trial NCT00032929?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.